{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:02:17Z","timestamp":1790726537017,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004628","name":"AstraZeneca UK Limited","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005646","name":"Actelion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012028","name":"Trombosestichting Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012028","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"HORIZON EUROPE Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103438","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:17:27Z","timestamp":1775099847000},"page":"103438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Andexanet alfa for the reversal of anticoagulation: Dutch practice data"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-1338-0010","authenticated-orcid":false,"given":"Jurjen F.","family":"Krommenhoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flip","family":"Kor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim","family":"Gal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willemijn E.M.","family":"Berkhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionne C.W.","family":"Braeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikus A.","family":"Klok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo ten","family":"Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renske H.","family":"Olie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103438_bib1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.rpth.2026.103438_bib2","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/STR.0000000000000069","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke"},{"key":"10.1016\/j.rpth.2026.103438_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/CIRCULATIONAHA.120.045769","article-title":"Factor Xa inhibitor-related intracranial hemorrhage","volume":"141","author":"Panos","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.103438_bib4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/bjh.13974","article-title":"Safety of prothrombin complex concentrate in healthy subjects","volume":"176","author":"Barco","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.103438_bib5","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1055\/s-0038-1636541","article-title":"Prothrombin complex concentrate for major bleeding on factor Xa inhibitors: a prospective cohort study","volume":"118","author":"Schulman","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103438_bib6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/bloodadvances.2018024133","article-title":"Management of direct factor Xa inhibitor\u2013related major bleeding with prothrombin complex concentrate: a meta-analysis","volume":"3","author":"Piran","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.103438_bib7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/jth.13894","article-title":"Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers","volume":"16","author":"Levy","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103438_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.thromres.2024.109172","article-title":"Prothrombin complex concentrate for direct factor Xa inhibitor-associated bleeding or before urgent surgery","volume":"243","author":"Shaw","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.103438_bib10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103438_bib11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.rpth.2026.103438_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103438_bib21","author":"Gray"},{"key":"10.1016\/j.rpth.2026.103438_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106070","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","volume":"195","author":"Giovino","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.rpth.2026.103438_bib15","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ajem.2020.11.043","article-title":"Real world utilization of andexanet alfa at a community hospital","volume":"45","author":"Santarelli","year":"2021","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2026.103438_bib16","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1002\/ajh.25326","article-title":"Andexanet alfa-the first 150 days","volume":"94","author":"Culbreth","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.103438_bib17","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/phar.2727","article-title":"Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures","volume":"42","author":"Bradshaw","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.rpth.2026.103438_bib18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/17474930251317385","article-title":"Andexanet alfa in patients with factor Xa inhibitor-associated intracranial hemorrhage: the prospective observational multicenter ASTRO-DE study","volume":"20","author":"Diener","year":"2025","journal-title":"Int J Stroke"},{"key":"10.1016\/j.rpth.2026.103438_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ajem.2025.07.037","article-title":"Andexanet alfa increases 30-day thrombotic events relative to four-factor prothrombin complex concentrate for factor Xa inhibitors-related intracerebral hemorrhage in veterans","volume":"97","author":"Rech","year":"2025","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.rpth.2026.103438_bib20","doi-asserted-by":"crossref","first-page":"939","DOI":"10.5811\/WESTJEM.60587","article-title":"Treatment of factor-Xa inhibitor-associated bleeding with andexanet alfa or 4 factor PCC: a multicenter feasibility retrospective study","volume":"24","author":"Singer","year":"2023","journal-title":"West J Emerg Med"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:16:41Z","timestamp":1790723801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926000968"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103438","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andexanet alfa for the reversal of anticoagulation: Dutch practice data","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103438","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103438"}}